Page 5 - 45337c10 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from 45337c10. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In 45337c10 Today - Breaking & Trending Today

Incyte Co. (NASDAQ:INCY) Shares Sold by Aviva PLC

Aviva PLC lessened its stake in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 19.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 129,955 shares of the biopharmaceutical company’s stock after selling 31,588 shares during the quarter. Aviva PLC owned about 0.06% […] ....

United States , Vijayk Iyengar , Aviva Plc , Salem Investment Counselors Inc , Glassman Wealth Services , Incyte Company Profile , Massmutual Trust Co , Parkside Financial Bank , Morgan Stanley , Incyte Corporation , Incyte Co , Free Report , Street Markets , Financial Bank , Wealth Services , Salem Investment Counselors , Investment Counselors , Get Free Report , Visit Holdingschannel , Incyte Daily , Nasdaq Incy , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Incyte (NASDAQ:INCY) Given New $81.00 Price Target at Citigroup

Incyte (NASDAQ:INCY – Free Report) had its target price lowered by Citigroup from $82.00 to $81.00 in a report published on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Other research analysts have also recently issued reports about the stock. StockNews.com upgraded shares of Incyte from a […] ....

United States , William Blair , Marketbeat Incyte , Vijayk Iyengar , Morgan Stanley , Parkside Financial Bank , Larson Financial Group , Cape Investment Advisory Inc , Turtle Creek Wealth Advisors , Incyte Corporation , Incyte Company Profile , Securities Exchange Commission , Free Report , Moderate Buy , Stock Down , Get Free Report , Exchange Commission , Investment Advisory , Street Markets , Financial Group , Creek Wealth Advisors , Financial Bank , Incyte Daily , Nasdaq Incy , Lower Price Target , Citigroup Inc ,

Royal Bank of Canada Raises Incyte (NASDAQ:INCY) Price Target to $65.00

Incyte (NASDAQ:INCY – Free Report) had its price objective lifted by Royal Bank of Canada from $63.00 to $65.00 in a research report report published on Wednesday, Benzinga reports. Royal Bank of Canada currently has a sector perform rating on the biopharmaceutical company’s stock. INCY has been the subject of several other research reports. Morgan […] ....

United States , Vijayk Iyengar , William Blair , Stifel Nicolaus , Incyte Corporation , Securities Exchange Commission , Prospera Financial Services Inc , Royal Bank , A Davidson , Us Bancorp , Silverarc Capital Management , Morgan Stanley , Free Report , Truist Financial , Moderate Buy , Trading Down , Get Free Report , Exchange Commission , Financial Services Inc , Capital Management , Clear Street Markets , Street Markets , Incyte Daily , Nasdaq Incy , Boost Price Target , Royal Bank Of Canada ,

Incyte (NASDAQ:INCY) Cut to "Market Perform" at JMP Securities

JMP Securities lowered shares of Incyte (NASDAQ:INCY – Free Report) from an outperform rating to a market perform rating in a research report sent to investors on Wednesday morning, Marketbeat Ratings reports. Other analysts also recently issued reports about the stock. William Blair reaffirmed an outperform rating on shares of Incyte in a report on […] ....

United States , Vijayk Iyengar , William Blair , Incyte Corporation , Cape Investment Advisory Inc , Securities Exchange Commission , Larson Financial Group , Turtle Creek Wealth Advisors , Parkside Financial Bank , Free Report , Marketbeat Ratings , Truist Financial , Moderate Buy , Get Free Report , Exchange Commission , Investment Advisory , Street Markets , Financial Group , Creek Wealth Advisors , Financial Bank , Incyte Daily , Nasdaq Incy , Jmp Securities ,

BMO Capital Markets Raises Incyte (NASDAQ:INCY) Price Target to $64.00

Incyte (NASDAQ:INCY – Get Free Report) had its price objective upped by investment analysts at BMO Capital Markets from $58.00 to $64.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “market perform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective would indicate a potential […] ....

United States , Vijayk Iyengar , Larson Financial Group , Turtle Creek Wealth Advisors , Cape Investment Advisory Inc , Parkside Financial Bank , Royal Bank , Incyte Corporation , Goldman Sachs Group , Morgan Stanley , Incyte Company Profile , Get Free Report , Street Markets , Investment Advisory , Financial Group , Financial Bank , Incyte Daily , Nasdaq Incy , Boost Price Target , Bmo Capital Markets ,